ResMed Inc boss Mick Farrell says the medical device maker is seeing more patients returning to get diagnosed for obstructive sleep apnoea across the world as nations control COVID-19.

The dual-listed giant revealed that first quarter revenue jumped by 9 per cent to $US751.9 million ($1.05 billion), on a constant currency basis. In August it said revenue had grown by low single digits in the the first month of the new fiscal year.